New preventive drugs for migraines were approved in Japan in 2021. The drugs contain antibodies that target a substance that plays a key role in migraines. In a clinical trial, around 70% of patients had a 50% drop in headache frequency. Separately, an item essential to patients called a headache diary has been developed into a smartphone app by a Japanese company. Their entries are shared with their doctors, making consultations smoother and more efficient.
